TARRYTOWN, N.Y., July 18 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) announced today that it has entered into
a multi-product research collaboration agreement with Roche to explore the
use of Emisphere's eligen(R) technology in feasibility studies for new oral
formulations of a number of Roche molecules. Roche will fund the research,
which will be conducted at both Roche and Emisphere.
Michael M. Goldberg, M.D., Chairman and Chief Executive Officer,
Emisphere Technologies, Inc., commented, "Establishing a research
collaboration agreement with Roche to investigate the application of our
technology on multiple compounds demonstrates the value Emisphere brings to
the product development process. Roche has been working with Emisphere for
a number of years and this new agreement further strengthens the
relationship between our two companies."
About The eligen(R) Technology
Emisphere's broad-based oral drug delivery technology platform, known
as the eligen(R) technology, is based on the use of proprietary, synthetic
chemical compounds, known as EMISPHERE(R) delivery agents, or "carriers."
These molecules facilitate or enable the transport of the therapeutic
macromolecules across biological membranes such as those of the
gastrointestinal tract, and exert their desired pharmacological effect. The
delivery agents have no known pharmacological activity themselves.
Emisphere's eligen(R) technology makes it possible to orally deliver a
therapeutic molecule without altering its chemical form or biological
integrity. Emisphere is pursuing shortened registration timelines for
currently marketed drug products whose performance is improved using the
eligen(R) technology through supplemental New Drug Applications or
505(b)(2) filings with the US FDA. Successful achievement of these
regulatory strategies may not require large-scale studies to support
product registration.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company pioneering
the oral delivery of otherwise injectable drugs. Emisphere's business
strategy is to develop oral forms of injectable drugs, either alone or with
corporate partners, by applying its proprietary eligen(R) technology to
those drugs or licensing its eligen(R) technology to partners who typically
apply it directly to their marketed drugs. Emisphere's eligen(R) technology
has enabled the oral delivery of proteins, peptides, macromolecules and
charged organics. Emisphere and its partners have advanced oral
formulations or prototypes of salmon calcitonin, heparin, insulin,
parathyroid hormone, human growth hormone and cromolyn sodium into clinical
trials. Emisphere has strategic alliances with world-leading pharmaceutical
companies. For further information, please visit our web site,
http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding the timing or potential
outcomes of research collaborations or clinical trials, any market that
might develop for any of Emisphere's product candidates and the sufficiency
of Emisphere's cash and other capital resources) are forward-looking
statements that involve risks and uncertainties, including, but not limited
to, the likelihood that future research will prove successful, the
likelihood that any product in the research pipeline will receive
regulatory approval in the United States or abroad, the ability of
Emisphere and/or its partners to develop, manufacture and commercialize
products using Emisphere's drug delivery technology, Emisphere's ability to
fund such efforts with or without partners, and other risks and
uncertainties detailed in Emisphere's filings with the Securities and
Exchange Commission, including those factors discussed under the caption
"Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615)
filed on March 16, 2006.
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com
CONTACT:
Stewart Siskind of Emisphere Technologies,
Inc., +1-914-785-4742, Info@Emisphere.com; or Media: Dan Budwick
of BMC Communications, +1-212-477-9007 ext. 14, for Emisphere
Technologies, Inc.
|
